Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-500 µl x 2 | 78641-2

Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-500 µl x 2 | 78641-2 | Gentaur US, UK & Europe Disrtribition

Category: Coronavirus/Lentivirus

Application: Screen or titrate neutralizing antibodies against SARS-CoV-2 Spike protein Model virus entry in Vero-E6 and ACE2-HEK293 cells

Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against viral infection.  The Omicron Variant was identified in South Africa in November of 2021. This variant has several mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. Compared with BA.1 (B.1.1.529), BA.1.1 has an additional R346K substitution in the spike protein. Vesicular stomatitis virus (VSV) is an enveloped, negative-stranded RNA virus that infects a wide range of animals and less frequently humans, causing mild flu-like symptoms. Its simple structure and its ability to grow in most mammalian cell types has made VSV a valuable tool to study virus entry, replication, and assembly. The glycoprotein of VSV (VSV-G), which binds to the LDL-receptor (low-density lipoprotein receptor), is responsible for the attachment and entry of VSV into a susceptible host cell. Recombinant VSV in which the glycoprotein was deleted (VSV Delta G) can accept viral envelop proteins from a variety of other viruses, allowing to generate pseudotypes that represent robust models to screen for neutralizing antibodies and other inhibitors of virus entry. The pseudoviruses can be engineered to transduce a reporter gene such as Firefly Luciferase or a fluorescent protein, so that viral entry can be monitored using luminescence or fluorescence. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) virus contains BA.1.1 variant SARS-CoV-2 Spike instead of VSV-G, which allows the pseudovirus to bind to ACE2-expressing cells.

Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility. As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells. Spike Mutations in BA.1.1 Omicron Variant: A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F

Product Type: Lentivirus

Shippement Condition: -80°C